TrialEuropean journal of haematology2020

A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Roman Hajek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.